SCHEMBL1786453

SCHEMBL1786453

O=C1OC=CC1S(=O)(=O)c1ccc(Cl)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.41
CYP3A4 P08684 1/20 0.41
MAPK1 P28482 1/20 0.41
CA1 P00915 4/20 0.38
CA2 P00918 4/20 0.38
CA12 O43570 3/20 0.38
CA3 P07451 3/20 0.38
CA4 P22748 3/20 0.38
CA6 P23280 3/20 0.38
CA5A P35218 3/20 0.38
CA7 P43166 3/20 0.38
CA9 Q16790 3/20 0.38
CA13 Q8N1Q1 3/20 0.38
CA14 Q9ULX7 3/20 0.38
CA5B Q9Y2D0 3/20 0.38
MMP2 P08253 3/20 0.35
KMT2A Q03164 2/20 0.35
MEN1 O00255 1/20 0.35
MMP1 P03956 1/20 0.35
MMP9 P14780 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30538414 0.67
SCHEMBL1786451 0.64 TSHR (0.61) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL11483426 0.63 ALDH1A1 (0.46) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL8990423 0.61 ALDH1A1 (0.62) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL21600737 0.61 PSEN1 (0.40) ALDH1A1CYP3A4MAPK1MMP2KMT2A
SCHEMBL217625 0.61 ALDH1A1 (0.48) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL4328031 0.60 ALDH1A1 (1.00) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL9313173 0.60 ALDH1A1 (1.00) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL22742 0.60 ALDH1A1 (1.00) ALDH1A1CYP3A4MAPK1CA1CA2
SCHEMBL9762603 0.60 ALDH1A1 (0.68) ALDH1A1CYP3A4MAPK1CA1CA2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2326629-B1 SULFONE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INT (DE) 2013-10-02 EP disclosed
US-8178568-B2 Sulfone compounds which modulate the CB2 receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2012-05-15 US disclosed
EP-2326629-A1 SULFONE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR Boehringer Ingelheim International GmbH (DE) 2011-06-01 EP disclosed
US-20110124696-A1 Sulfone Compounds Which Modulate The CB2 Receptor BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2011-05-26 US disclosed
WO-2010005782-A1 SULFONE COMPOUNDS WHICH MODULATE THE CB2 RECEPTOR BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2010-01-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110124696-A1 Sulfone Compounds Which Modulate The CB2 Receptor CNR2, CNR1, TRPV1 ALDH1A1 2844/4885CYP3A4 1414/4885MAPK1 1511/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.